Navigation Links
$3.7 million trial uses genes to balance risks, benefits of blood thinner
Date:4/8/2010

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

The multicenter study, led by researchers at Washington University School of Medicine in St. Louis, will evaluate customized warfarin dosage based on patient genetics and will test which range of blood clotting is optimal in orthopedic patients.

Blood clots contribute to the death of 100,000 Americans every year. Most of these deaths occur suddenly, so prevention with a blood thinner, or anticoagulant, such as warfarin (Coumadin) is widely regarded to be the best form of protection. However, a number of factors including drug interactions and genetics can interfere dangerously with warfarin, making it tricky to pinpoint the correct dose.

To help determine the best way to establish the right dose, knee or hip replacement surgery patients at Barnes-Jewish Hospital and several other institutions will be eligible to enroll in the Genetics InFormatics Trial of Warfarin (GIFT).

"Without any anticoagulant, orthopedic patients have a nearly 50 percent chance of having a blood clot after hip or knee replacement," says Brian Gage, MD, associate professor of medicine at Washington University and lead investigator of the trial. "These are the people at highest risk for blood clots, and because they've just had surgery they are also at high risk for bleeding. This balance is why this question of warfarin dosing is critical. Finding the right dose is like walking a tightrope."

The National Heart, Lung, and Blood Institute will fund the study. Collaborating institutions include the University of Utah, Intermountain Health Care, and the Hospital for Special Surgery in New York. Gage and colleagues hope to enroll 1,600 patients recovering from hip or knee replacement surgery, which will allow them to investigate two problems that make determining optimal warfarin dosage
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Structure of 450 million year old protein reveals evolutions steps
2. First orchid fossil puts showy blooms at some 80 million years old
3. SyntheMed Completes $2.8 Million Equity Financing
4. Rutgers Genetics receives $7.8 million for autism research
5. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
6. UD leads $5.3-million research project on rice epigenetics
7. Rutgers high school outreach gets $3 million boost from NSF
8. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
9. UD leads $5.3-million research project on rice epigenetics
10. $22 million gift from Alfred Taubman launches new biomedical research institute
11. Nanobiosym awarded $2 million DTRA contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... with injury better than others. A flesh wound or muscle ... will heal. The prognosis for a heart attack, on the ... been thought that cardiac cells (cardiomyocytes) lack the capacity for ... from a heart attack. However, recent evidence suggests that the ...
... Therapeutics, today announced the grant of a major patent, ... Trademark Office on microarray products allowing the specific detection ... for the discovery of alternative RNA splicing events. The ... of five oligonucleotides for the detection of each splice ...
... results in irreversible damage to the heart that ... results from the limited ability of the myocardium ... from Tufts University now document the existence of ... stem cells with therapeutic potency for myocardial tissue ...
Cached Biology News:Heart repair gets new muscle 2Products containing specific probes for detecting alternative splice forms protected 2
(Date:5/20/2015)... , May 20, 2015 Veracyte, ... preliminary data demonstrating the ability of the company,s ... (IPF) from other interstitial lung diseases (ILDs) using ... classifier,s potential to help thousands of patients avoid ... in IPF diagnosis – a frequent challenge for ...
(Date:5/20/2015)... , May 20, 2015  Select Medical Corporation ... Federal Trade Commission granted early termination of the ... Act of 1976, as amended, applicable to the ... Corporation, a joint venture that Select has created ... As previously announced, MJ Acquisition Corporation has ...
(Date:5/20/2015)... 20, 2015  Marc Tessier-Lavigne, president of The ... $100 million from The Marie-Josée and Henry R. ... building that will be the centerpiece of the ... Henry R. Kravis Research Building, two stories high, ... approximately three city blocks following the shoreline of ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... of the "Bone Morphogenetic Proteins Market (Types ... Reconstructive and Oral - Maxillofacial) - Global Industry ... - 2022" report to their offering. ... studied based on the types of recombinant BMPs, ...
Breaking Biology Technology:Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ... development and commercialization of novel drugs in the therapeutic ... that it has submitted a full proposal to the ... BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense .  It ...
... imaging system, scientists have tracked a group of near-infrared ... the body and out again, providing a description of ... could be used in developing therapeutic agents to treat ... of the health effects of air pollution. ...
... 2010 Financial Results ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11
Selenoprotein P Purified Anti-Mouse clone 35, Isotype Mouse IgG 2b , 50 µg Consult technical datasheet for details....
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
... isomers are predominantly used for labeling proteins, ... labeling peptides and nucleotides because they give ... often required in the conjugation processes. 5-TAMRA ... labeling peptides and proteins. 6-TAMRA is predominately ...
Biology Products: